Artemether-Lumefantrine Versus Chloroquine for the Treatment of Uncomplicated Plasmodium knowlesi Malaria: An Open-Label Randomized Controlled Trial CAN KNOW

by Matthew J Grigg, Timothy William, Bridget E Barber et al.
Clinical Infectious Diseases, Vol. 66, Issue 2, 6 January 2018

8 pp. 318 kB

Plasmodium knowlesi is reported increasingly across Southeast Asia and is the most common cause of malaria in Malaysia. A randomized controlled trial was conducted in 3 district hospitals in Sabah, Malaysia to compare the efficacy of Artemether-Lumefantrine (AL) against chloroquine (CQ) for uncomplicated knowlesi malaria. The authors conclude that AL is highly efficacious for treating uncomplicated knowlesi malaria; its excellent tolerability and rapid therapeutic response allow earlier hospital discharge, and support its use as a first-line artemisinin-combination treatment policy for all Plasmodium species in Malaysia.

(Visited 5 times, 1 visits today)
This entry was posted in Essential Medicines, Malaria. Bookmark the permalink.